Assessment of the efficacy and safety of zoledronic acid in the treatment of bone metastases-related pain in patients with prostate cancer.

Trial Profile

Assessment of the efficacy and safety of zoledronic acid in the treatment of bone metastases-related pain in patients with prostate cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Cancer metastases; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms TRAPEZE
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Dec 2009 Actual patient number (61) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top